AMAG - AMAG Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

19.35

-0.50 (-2.52%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	19.85
Open	19.80
Bid	17.30 x 1000
Ask	22.80 x 400
Day's Range	19.80 - 19.95
52 Week Range	11.93 - 24.85
Volume	480,587
Avg. Volume	1,217,622

Market Cap	659.62M
Beta	0.10
PE Ratio (TTM)	N/A
EPS (TTM)	-5.71
Earnings Date	Apr 30, 2018 - May 4, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	20.90

Trade prices are not sourced from all markets

All

News

Press Releases

Thomson Reuters StreetEvents11 days ago
Edited Transcript of AMAG presentation 8-Mar-17 3:25pm GMT
AMAG Pharmaceuticals Inc at Raymond James Institutional Investors Conference
Zacks23 days ago
AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswire26 days ago
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
WALTHAM, Mass., March 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for bremelanotide, which AMAG in-licensed ...
PR Newswire26 days ago
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.
GlobeNewswire2 months ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., March 05, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. Cowen and Company 38 th Annual Health Care Conference ...
Zacks2 months ago
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of AMAG earnings conference call or presentation 27-Feb-18 1:00pm GMT
Q4 2017 AMAG Pharmaceuticals Inc Earnings Call
Associated Press2 months ago
AMAG Pharmaceuticals tops Street 4Q forecasts
The Waltham, Massachusetts-based company said it had profit of 10 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
GlobeNewswire2 months ago
AMAG Reports 2017 Financial Results and Company Update
2017 GAAP Revenue Increased 15% Year-over-Year. February 2018: Company Secures Two U.S. Food and Drug Administration Approvals.
ACCESSWIRE2 months ago
AMAG Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 8:00 AM ...
Motley Fool2 months ago
These 2 Biotech Stocks Are Soaring. Can They Keep It Up?
Find out why these two stocks have surged this year to see if there might be more gains ahead.
GlobeNewswire2 months ago
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET
WALTHAM, Mass., Feb. 20, 2018-- AMAG Pharmaceuticals, Inc. today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial ...
ACCESSWIRE2 months ago
Blog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk Women
LONDON, UK / ACCESSWIRE / February 20, 2018 / Active-Investors.com has just released a free research report on AMAG Pharma, Inc. (NASDAQ: AMAG) ("AMAG"). If you want access to this report all ...
Moody's2 months ago
AMAG Pharmaceuticals, Inc. -- Moody's says AMAG's Makena auto injector approval is credit positive; ratings unaffected at this time
Moody's Investors Service says a supplemental regulatory approval of AMAG Pharmaceuticals, Inc.'s ("AMAG") next generation Makena drug-device combination product is credit positive. The approval ...
Market Realist2 months ago
Exploring AMAG Pharmaceuticals’ Financial Performance
What Led to Stellar Rise of AMAG Pharmaceuticals in February?
Market Realist2 months ago
Label Expansion of Ferahame Bodes Well for AMAG Pharmaceuticals
What Led to Stellar Rise of AMAG Pharmaceuticals in February?
Market Realist2 months ago
A Look at AMAG Pharmaceuticals’ Collaborations
What Led to Stellar Rise of AMAG Pharmaceuticals in February?
Market Realist2 months ago
Analyst Ratings for AMAG Pharmaceuticals and Peers in February
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
GlobeNewswire2 months ago
Recent Analysis Shows SBA Communications, AMAG Pharmaceuticals, Galectin Therapeutics, Xilinx, J.B. Hunt Transport Services, and Southern Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SBA ...
Investor's Business Daily2 months ago
This Biotech Stock Pops 30% On FDA Nod — 'Slamming Door' On Woes
Amag increased its value by nearly a third Thursday after U.S. regulators approved a second drug from the biotech this month.
InvestorPlace2 months ago
Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are skyrocketing Thursday as the company received regulatory approval for one of its treatments. The company announced that the U.S. Food and Drug Administration gave the green light for its Makena subcutaneous auto injector drug-device combination product, which is a treatment that is designed to reduce the risk of preterm birth in women who are pregnant with one baby, as well as those who spontaneously delivered one preterm baby in the past. AMAG Pharmaceuticals developed the medication along with Antares Pharma Inc (NASDAQ:ATRS) as the two companies agreed back in a 2014 deal that AMAG will make and supply the drug product to Antares.
Motley Fool2 months ago
Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today
Favorable regulatory news causes traders to cheer.
Benzinga2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Cisco Systems, Inc. (NASDAQ: CSCO ) stock was trading ...
MarketWatch2 months ago
Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector
Shares of Antares Pharma Inc. and Amag Pharmaceuticals soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector drug-device ...
GlobeNewswire2 months ago
Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector
EWING, N.J., Feb. 14, 2018-- Antares Pharma, Inc. today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals. Food and Drug Administration ...